Literature DB >> 17119861

Anti-p53 antibodies in patients with dermatomyositis/polymyositis.

Yoshihiro Mimura1, Norihito Yazawa, Zenshirou Tamaki, Ryuichi Ashida, Masatoshi Jinnin, Yoshihide Asano, Yayoi Tada, Masahide Kubo, Hironobu Ihn, Kunihiko Tamaki.   

Abstract

Dermatomyositis/polymyositis (DM/PM), which is often accompanied by various immunological abnormalities, was reported to be associated with an increased incidence of malignancies. In this study, we analyzed serum levels of anti-p53 antibody (anti-p53 Ab) in DM/PM patients and in normal controls. Serum levels of anti-p53 Abs were significantly higher in DM/PM patients than those in healthy controls. However, there was no significant difference between serum levels in patients with malignancies and those in patients without malignancies. Anti-p53 Abs were positive in 13% (4 out of 31) of the DM/PM patients. Of these four patients, only one had an internal malignancy. Immunoglobulin G levels were significantly higher in patients positive for anti-p53 Ab than those who were not. These results seemed to suggest that the presence of anti-p53 Abs in DM/PM patients is due to immunological abnormalities in this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119861     DOI: 10.1007/s10067-006-0473-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

1.  Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis.

Authors:  J L Pablos; B Santiago; M Galindo; P E Carreira; C Ballestin; J J Gomez-Reino
Journal:  J Pathol       Date:  1999-05       Impact factor: 7.996

Review 2.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

3.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

4.  Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study.

Authors:  B Sigurgeirsson; B Lindelöf; O Edhag; E Allander
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

5.  Clinical implication of anti-p53 antibodies and p53-protein in pancreatic disease.

Authors:  Gakuji Ohshio; Hirofumi Suwa; Masayuki Imamura
Journal:  Int J Gastrointest Cancer       Date:  2002

6.  Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.

Authors:  Y Asano; H Ihn; K Yamane; N Yazawa; M Kubo; M Fujimoto; K Tamaki
Journal:  Arthritis Rheum       Date:  2001-06

7.  Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer.

Authors:  D Coomber; N J Hawkins; M Clark; A Meagher; R L Ward
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

8.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer.

Authors:  L V Crawford; D C Pim; R D Bulbrook
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396

9.  Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers.

Authors:  K Angelopoulou; E P Diamandis; D J Sutherland; J A Kellen; P S Bunting
Journal:  Int J Cancer       Date:  1994-08-15       Impact factor: 7.396

10.  The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study.

Authors:  L A Manchul; A Jin; K I Pritchard; J Tenenbaum; N F Boyd; P Lee; T Germanson; D A Gordon
Journal:  Arch Intern Med       Date:  1985-10
View more
  6 in total

1.  Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases.

Authors:  Takashi Himoto; Hirohito Yoneyama; Kazutaka Kurokohchi; Michio Inukai; Hisashi Masugata; Fuminori Goda; Reiji Haba; Seishiro Watanabe; Shoichi Senda; Tsutomu Masaki
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

Review 2.  The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.

Authors:  Cheng Wang; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

Review 3.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

Review 4.  The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target.

Authors:  Alessandra Fierabracci; Marsha Pellegrino
Journal:  Int J Mol Sci       Date:  2016-11-25       Impact factor: 5.923

5.  Activation of innate immunity by mitochondrial dsRNA in mouse cells lacking p53 protein.

Authors:  Dagmara M Wiatrek; Maria E Candela; Jiří Sedmík; Jan Oppelt; Liam P Keegan; Mary A O'Connell
Journal:  RNA       Date:  2019-03-20       Impact factor: 4.942

6.  Effect of p53 activation through targeting MDM2/MDM4 heterodimer on T regulatory and effector cells in the peripheral blood of Type 1 diabetes patients.

Authors:  Marsha Pellegrino; Gianandrea Traversi; Andrea Arena; Marco Cappa; M Manuela Rosado; Marco Andreani; Domenico V Delfino; Fabiola Moretti; Alessandra Fierabracci
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.